Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: A randomized controlled trial

Journal of Viral Hepatitis

Volumn 21, Issue 5, 2014, Pages 348-356

  Yokoyama, S ^a   Takahashi, S ^a   Kawakami, Y ^a   Hayes, C N ^a   Kohno, H ^b   Tsuji, K ^c   Aisaka, Y ^d   Kira, S ^d   Yamashina, K ^e   Nonaka, M ^f   Moriya, T ^g   Kitamoto, M ^h   Aimitsu, S ^e   Nakanishi, T ^f   Kawakami, H ⁱ   Chayama, K ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e HIROSHIMA GENERAL HOSPITAL   (Japan)

^f Miyoshi Chuo Hospital   (Japan)

^g Chugoku Rousai Hospital   (Japan)

^h HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

ⁱ Kawakami Clinic   (Japan)

Author keywords

chronic hepatitis C; pegylated interferon; ribavirin; vitamin D

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; VITAMIN D; ALPHA INTERFERON; ANTIVIRUS AGENT; VITAMIN;

ADULT; AGED; ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY NEUROSIS; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; CLASSIFICATION; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VITAMIN D; VITAMINS;

EID: 84898491795     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12146     Document Type: Article

References (35)

1. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9): 558-567.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45 (4): 529-538.
3. Hoofnagle JH,. Course and outcome of hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S21-S29.
4. Seeff LB, Hoofnagle JH,. Appendix: the National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7 (1): 261-287.
5. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838. United States: 2009 Massachusetts Medical Society.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
7. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
8. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 (11): 1014-1024.
9. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with. Lancet 2010; 376 (9742): 705-716.
10. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207-1217.
11. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 (25): 2417-2428.
12. Barritt ASt, Fried MW,. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C. Gastroenterology 2012; 142 (6): 1314-1323.e1.
13. Petta S, Camma C, Scazzone C, et al,. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51 (4): 1158-1167.
14. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N,. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17 (47): 5184-5190.
15. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75. England: 2011. Published by Elsevier B.V.
16. Reau N, Satoskar R, Te H, et al,. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol 2011; 106: 452-458. United States.
17. Yu ML, Dai CY, Huang JF, et al,. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47 (6): 1884-1893.
18. Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP,. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther 2009; 14 (8): 1139-1148.
19. Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R,. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database Syst Rev 2012; 9: CD008516.
20. Di Martino V, Richou C, Cervoni JP, et al,. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54 (3): 789-800.
21. DeLuca HF,. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: 1689S-1696S. United States.
22. Dusso AS, Brown AJ, Slatopolsky E,. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28. United States.
23. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C,. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-496. England: 2010 Elsevier Ltd.
24. Compston JE,. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 1986; 27 (9): 1073-1090.
25. Gal-Tanamy M, Bachmetov L, Ravid A, et al,. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54 (5): 1570-1579.
26. Metz P, Dazert E, Ruggieri A, et al,. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 2012; 56 (6): 2082-2093.
27. Matsumura T, Kato T, Sugiyama N, et al,. 25-hydroxyvitamin D(3) suppresses hepatitis C virus production. Hepatology 2012; 56 (4): 1231-1239.
28. Peterlik M, Cross HS,. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35: 290-304. England.
29. Kitson MT, Roberts SK,. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012; 57 (4): 897-909.
30. Lange CM, Bojunga J, Ramos-Lopez E, et al,. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-893. England: 2010 European Association for the Study of the Liver. Published by Elsevier B.V.
31. Lange CM, Bibert S, Kutalik Z, et al,. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS ONE 2012; 7: e40159. United States.
32. Bitetto D, Fattovich G, Fabris C, et al,. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53 (4): 1118-1126.
33. Martinot-Peignoux M, Comanor L, Minor JM, et al,. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. J Viral Hepat 2006; 13 (10): 701-707.
34. Kitson MT, Dore GJ, George J, et al,. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013; 58 (3): 467-472.
35. Lin K, Perni RB, Kwong AD, Lin C,. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006; 50 (5): 1813-1822.